Comparative Pharmacology
Head-to-head clinical analysis: AMNESTEEM versus TARGRETIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMNESTEEM versus TARGRETIN.
AMNESTEEM vs TARGRETIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Retinoid that binds to and activates retinoic acid receptors (RARs), thereby normalizing keratinocyte differentiation and reducing sebum production.
Selective retinoid X receptor (RXR) agonist that modulates gene expression involved in cell differentiation, proliferation, and apoptosis.
0.5-1.0 mg/kg/day orally in 2 divided doses
300 mg/m2 orally once daily.
None Documented
None Documented
Terminal elimination half-life: 10-20 hours (mean 17 hours) in patients with normal renal function; prolonged in severe renal impairment
Terminal elimination half-life is approximately 7 hours (range 3–10 hours) for the parent drug. The active metabolite (bexarotene glucuronide) has a half-life of about 9 hours. Clinically, steady state is reached within 3–5 days.
Renal (65-83% as unchanged drug and metabolites), fecal (15-35% as metabolites)
Primarily metabolized in the liver via CYP3A4; elimination is mainly through hepatobiliary excretion into feces. Renal excretion is minimal (<3% as unchanged drug).
Category C
Category C
Retinoid
Retinoid